Oral contraceptives can cause liver damage, but the risk is low for most people. The spectrum runs from mild, reversible enzyme elevations that many users never notice all the way to rare but serious outcomes like drug-induced liver injury, benign liver tumors, and blood clots in the liver’s veins. The estrogen component bears most of the blame, and today’s lower-dose formulations carry less hepatic risk than the pills prescribed decades ago. Still, the liver is one of the organs most directly affected by hormonal contraception, and the details matter more than a simple yes-or-no answer suggests.
Why the Liver Is in the Crosshairs
Every pill you swallow passes through the liver before reaching the rest of your body. This “first-pass” metabolism means the liver sees a concentrated dose of synthetic estrogen and progestin with each tablet. Estrogen, in particular, interferes with the transport of bile acids, the digestive compounds the liver produces and exports into the intestine. When bile flow slows or stalls, a condition called cholestasis develops. The main way estrogen triggers this is by disrupting the enzymes and transporter proteins that move bile acids out of liver cells.1PubMed Central. The Pathological Mechanisms of Estrogen-Induced Cholestasis: Current Perspectives Think of it as a plumbing slowdown: bile backs up inside liver cells, and the retained bile acids irritate and damage those cells from the inside.
This mechanism explains why nearly every liver-related side effect of the pill is more strongly linked to the estrogen component than to the progestin. It also explains why lower-estrogen formulations have fewer liver complications. A study comparing adverse liver reaction reports across different pill generations found that medium-estrogen pills caused fewer problems than high-estrogen pills, with a further (though smaller) drop when low-estrogen formulations were used.2PubMed. Liver damage from low-dose oral contraceptives The shift from older high-dose pills to today’s formulations containing far less estrogen has meaningfully reduced the liver risks associated with the pill, though it hasn’t eliminated them entirely.
Drug-Induced Liver Injury
The most direct form of liver damage from birth control is drug-induced liver injury, or DILI. This is an idiosyncratic reaction, meaning it’s unpredictable and depends on individual susceptibility rather than dose alone. In one large series of over 1,200 DILI patients, about 3.5% of cases were attributed to oral contraceptives.3Journal of Clinical and Experimental Hepatology. Clinical Features, Laboratory Characteristics and Outcome from Oral Contraceptives-induced Liver Injury in 43 Consecutive Patients and a Brief Review of Published Reports Among those 43 patients, roughly half had taken combination estrogen-progestin pills and about half had been on progestin-only therapy. Nearly half developed jaundice, and the liver injury pattern varied: some had primarily liver-cell damage, some had bile-flow problems, and about a third had a mix of both.
Most patients recovered fully after stopping the medication, with liver tests returning to normal in about two months on average. But the outcomes weren’t universally good. Four patients in that series died, three from acute liver failure and one who had underlying chronic liver disease that worsened.3Journal of Clinical and Experimental Hepatology. Clinical Features, Laboratory Characteristics and Outcome from Oral Contraceptives-induced Liver Injury in 43 Consecutive Patients and a Brief Review of Published Reports Fatal outcomes are exceptionally rare relative to the millions of people using hormonal contraception worldwide, but they underscore why unexplained jaundice or severe fatigue in someone recently started on the pill warrants prompt medical evaluation.
Published case reports illustrate the typical pattern. In one case, a 29-year-old woman developed fatigue, itching, and elevated liver enzymes just one week after starting a combination pill. She had no history of alcohol use or liver disease, though her mother and sister had experienced cholestasis during pregnancy. After viral hepatitis and autoimmune disease were ruled out, a liver biopsy showed mild cholestasis, and her symptoms resolved completely once the pill was stopped.4American Journal of Gastroenterology. Oral Contraception Woes: Idiosyncratic Drug Induced Liver Injury That family history of pregnancy-related cholestasis is a red flag; people with this background face a higher risk of recurrence on hormonal contraception and are generally advised to avoid estrogen-containing methods entirely.5PubMed. Hepatobiliary complications of oral contraceptives
Benign Liver Tumors
One of the best-established liver effects of the pill is its link to hepatocellular adenoma, a benign tumor of liver cells. These tumors are overwhelmingly found in women of reproductive age, and prolonged oral contraceptive use is the strongest known risk factor. An early landmark study found that women who developed adenomas had used oral contraceptives for an average of about 73 months, roughly double the duration seen in matched controls. Hemorrhage into the tumor was a frequent complication, sometimes triggered by the onset of menstruation.6New England Journal of Medicine. Liver-cell adenomas associated with use of oral contraceptives
The encouraging news is that these tumors often shrink or disappear once the pill is discontinued. In a study tracking adenomas after pill cessation, over a third showed at least 30% regression within a median of about 15 months, and a small number regressed completely. Larger tumors actually shrank faster than smaller ones.7PubMed Central. The effect of oral contraceptive pill cessation on hepatocellular adenoma diameter: A retrospective cohort study An earlier case series documented complete regression in all three patients followed after stopping the pill, leading the authors to suggest that watchful waiting after pill discontinuation could sometimes replace surgery.8Gastroenterology. Regression of liver cell adenoma: A follow-up study of three consecutive patients after discontinuation of oral contraceptive use
For people already diagnosed with hepatocellular adenoma who need contraception, the type of hormone matters. Estrogen-containing methods are associated with tumor growth, while progestin-only contraceptives appear to be a safer bet. A retrospective study found that adenoma diameters shrank by about 15% on average with progestin-only agents, compared to nearly 30% growth in patients with estrogen exposure.9Contraception. Influence of progestin-only hormonal use on hepatocellular adenomas: A retrospective cohort study A 2025 systematic review of hormonal contraception safety in liver disease confirmed this pattern: estrogen-containing methods were linked to adenoma progression, while progestin-only methods generally kept lesions stable.10Contraception. Safety of hormonal contraception among women with liver disease: an updated systematic review
Focal nodular hyperplasia (FNH) is a different benign liver lesion that sometimes gets lumped together with adenoma but behaves differently. Although it was long assumed that the pill promotes FNH, a comprehensive review concluded that a causal role for oral contraceptives has not been proven.11PubMed Central. Focal Nodular Hyperplasia: A Comprehensive Review with a Particular Focus on Pathogenesis and Complications A large study found that neither the size nor the number of FNH lesions was influenced by oral contraceptive use, and that changes in size during follow-up were rare and unrelated to the pill.12PubMed. Oral contraceptive use and focal nodular hyperplasia of the liver One noteworthy observation is that about a quarter of FNH patients also have liver hemangiomas (another benign growth), and this association was found exclusively among women who had used oral contraceptives, with longer use linked to higher likelihood.13Gastroenterology. Association of focal nodular hyperplasia and hepatic hemangioma So while FNH itself may not be driven by the pill, the pill might make it more clinically visible by promoting the growth of coexisting vascular lesions.
What About Liver Cancer?
For decades, the relationship between oral contraceptives and liver cancer was a source of genuine concern. Some older studies found alarming associations. A case-control study from the late 1980s reported that eight of nine women with hepatocellular carcinoma had used oral contraceptives, compared to only about a third of controls.14PubMed. Oral contraceptive use and liver cancer A 1986 study found that eight or more years of pill use was associated with roughly a four-fold increased risk of liver cancer, which jumped higher when patients with hepatitis B were excluded.15Br Med J (Clin Res Ed). Oral contraceptives and hepatocellular carcinoma Those numbers got a lot of attention, and understandably so.
But those studies were conducted in an era of higher-dose pills, smaller sample sizes, and less rigorous control for confounders like hepatitis infection. The picture has shifted considerably with more recent and much larger data. A 2025 meta-analysis pooling 23 observational studies with over 5,400 liver cancer cases found essentially no increased risk for ever-users of oral contraceptives compared to never-users. Looking at duration, there was a very small increase in risk per five years of use, on the order of about 6%, and this held similarly for both hepatocellular carcinoma and intrahepatic cholangiocarcinoma.16The Lancet. Oral contraceptive use and risk of liver cancer: a population-based study, systematic review, and meta-analysis That is a far cry from the four-fold or higher risks reported earlier. The absolute risk of liver cancer remains low in populations where hepatitis B and C are well controlled, so even a small relative increase translates to very few additional cases.
Blood Clots in the Liver’s Veins
Budd-Chiari syndrome occurs when blood clots block the veins that drain the liver, leading to liver congestion, pain, and potentially liver failure. Oral contraceptives are a recognized contributing factor. A multicenter case-control study of 33 women with hepatic vein thrombosis found that pill users faced roughly 2.4 times the risk compared to nonusers.17PubMed. Hepatic vein thrombosis (Budd Chiari syndrome): possible association with the use of oral contraceptives The risk was particularly pronounced in women who already had an underlying blood disorder that increased their clotting tendency. In those cases, the pill’s own pro-clotting effects appeared to tip an already precarious balance toward full-blown thrombosis.18PubMed. Oral contraceptives and hepatic vein thrombosis
This is worth knowing because Budd-Chiari syndrome is one of the few pill-related liver problems that can become an emergency. Symptoms include sudden onset of upper abdominal pain, swelling of the abdomen from fluid buildup, and rapid liver enlargement. Anyone on the pill who develops these symptoms needs urgent evaluation. The condition is rare in the general population, but it illustrates how the pill’s effects on coagulation can sometimes affect the liver indirectly through vascular damage rather than direct toxicity to liver cells.
Effects on Gallbladder Bile
Though the gallbladder is a separate organ, its function is tightly connected to the liver, and oral contraceptives alter bile composition in ways that promote gallstone formation. A classic study in the New England Journal of Medicine measured gallbladder bile in women on and off the pill and found that bile was significantly more saturated with cholesterol during contraceptive use. The proportions of bile acids also shifted in a direction that favors cholesterol crystallization.19PubMed. Effects of oral contraceptives on the gallbladder bile of normal women These changes help explain the well-documented higher rate of gallbladder disease among pill users. It isn’t liver damage in the strict sense, but it’s a hepatobiliary consequence that clinicians and patients should be aware of.
Do Liver Enzymes Rise in Everyday Users?
You don’t need to develop jaundice or a tumor for the pill to leave a trace on your liver. A comparative study of hormonal contraceptive users versus non-users found that liver enzyme levels were roughly double in the users. For instance, ALT (a standard marker of liver cell health) averaged about 36 in users versus 17 in non-users, and AST showed a similar pattern.20PubMed Central. Assessment of liver function tests of women taking hormonal contraceptives at University of Gondar comprehensive specialized hospital and Family Guidance Association of Gondar (FGAE), 2022; a comparative cross-sectional study Bilirubin levels, another indicator of liver and bile duct function, were also elevated. The study noted that the degree of elevation varied with the type of contraceptive, how long it had been used, and adherence patterns.
Does this mean everyday pill use is quietly harming the liver? Not necessarily. Mild enzyme elevations in the absence of symptoms don’t always signal tissue damage; they can reflect increased metabolic activity as the liver processes the hormones. A study of the etonogestrel implant (a progestin-only method) found a statistically significant increase in ALT at six months but concluded that the changes did not reach levels considered unhealthy.21Contraception. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels That said, if you’re already being monitored for a liver condition, these shifts matter because they can blur the interpretation of routine blood work.
The Fatty Liver Puzzle
Fatty liver disease, also known as MASLD (formerly NAFLD), is the most common chronic liver condition worldwide, and its relationship with hormonal contraception is surprisingly complicated. One analysis of national health data found that women currently using combination oral contraceptives had about half the odds of fatty liver compared to women who had never used them.22PubMed Central. Oral contraceptive pill use is associated with reduced odds of nonalcoholic fatty liver disease in menstruating women: results from NHANES III The relationship weakened after adjusting for body weight, suggesting that some of the apparent protection may be intertwined with metabolic factors rather than a direct liver effect.
Progestin-only methods, on the other hand, may tell a different story. In a study of women with a history of gestational diabetes, progestin-only contraceptives (particularly oral progestins and injectable depot medroxyprogesterone) were associated with over four times the odds of fatty liver disease compared to non-hormonal methods. Combination pills showed no significant association with fatty liver risk in the same study.23Contraception. Contraception and nonalcoholic fatty liver disease in women with prior gestational diabetes mellitus This creates an awkward tension: estrogen-containing pills appear somewhat protective against fatty liver, while the progestin-only options generally considered safer for acute liver toxicity and tumor risk may contribute to fat accumulation in the liver. For most people this won’t change contraceptive choices, but for someone already at high risk for fatty liver disease, it’s worth discussing with a clinician.
Who Needs to Be Especially Careful
Certain groups face outsized risk from hormonal contraception’s liver effects. The clearest guidance applies to anyone with active liver disease. Estrogen-containing methods are considered contraindicated during acute liver illness, and clinical guidelines have been consistent on this point for decades.24PubMed. Contraception in the patient with liver disease Progestin-only contraceptives appear safer and are generally offered as an alternative, along with barrier methods and intrauterine devices.
Beyond active liver disease, several other situations call for extra caution:
- History of cholestasis in pregnancy: Women whose bile flow slowed during a previous pregnancy face a high risk of the same thing happening on estrogen-containing contraception, and are typically advised to avoid it altogether.
- Existing hepatocellular adenoma: Estrogen promotes growth of these tumors, making estrogen-containing pills a poor choice. Progestin-only methods are the preferred hormonal option.
- Clotting disorders: Conditions that increase blood-clot risk amplify the chance of hepatic vein thrombosis on the pill. If you’ve been told you have a clotting predisposition, your prescriber should factor that into any contraception decision.
- Concurrent medications metabolized by the liver: Drugs that inhibit the enzymes responsible for breaking down synthetic hormones can raise circulating estrogen and progestin levels, potentially increasing the risk of liver-related side effects and thrombosis.25PubMed Central. Combined Oral Contraceptives As Victims of Drug Interactions
When Progestin-Only Methods Aren’t the Perfect Swap
The standard clinical reflex when a patient has a liver concern is to switch from a combination pill to a progestin-only option. For most liver-related complications, this is well supported. Progestin-only methods don’t carry the same cholestasis risk, they don’t fuel adenoma growth the way estrogen does, and they sidestep the bile-composition changes that drive gallstone formation.
But progestin-only contraception isn’t entirely liver-neutral. As noted earlier, progestin-only pills and injectable progestins have been linked to higher rates of fatty liver in at-risk women, a finding that complicates the idea that removing estrogen solves every hepatic concern.23Contraception. Contraception and nonalcoholic fatty liver disease in women with prior gestational diabetes mellitus And in the large DILI case series, about half the contraceptive-related liver injuries involved progestin monotherapy, not combination pills.3Journal of Clinical and Experimental Hepatology. Clinical Features, Laboratory Characteristics and Outcome from Oral Contraceptives-induced Liver Injury in 43 Consecutive Patients and a Brief Review of Published Reports Drug-induced liver injury is an idiosyncratic reaction, and swapping one hormone for another doesn’t guarantee safety. For people with liver disease who want or need contraception, the IUD and barrier methods remain the most liver-agnostic options on the table.